Names | |
---|---|
Preferred IUPAC name
3-(Methanesulfonyl)propanenitrile | |
Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
ChEMBL |
|
ChemSpider |
|
DrugBank |
|
ECHA InfoCard | 100.255.888 |
EC Number |
|
IUPHAR/BPS
|
|
KEGG |
|
PubChem CID
|
|
UNII |
|
InChI
| |
SMILES
| |
Properties | |
Chemical formula
|
C4H7NO2S |
Molar mass | 133.17 g·mol−1 |
Hazards | |
GHS labelling: | |
Pictograms
|
|
Signal word
|
Warning |
Hazard statements
|
H302, H315, H319, H335 |
Precautionary statements
|
P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, P501 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
|
Dapansutrile (OLT1177) is an inhibitor of the NLRP3 (nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3) inflammasome.[1]
An inflammasome can be defined as an immune system receptor that induces inflammation through the activation of caspase 1 and caspase 11 when it is triggered by damaged cells, microbial pathogens, and stress.[3] NLRP3 is a canonical inflammasome.[3] The NLRP3 inflammasome comprises NLRP3, the apoptosis spec-like protein (ASC) and the caspase-1[2] (Figure 1). The NLRP3 inflammasome forms by binding to pattern recognition receptors (PRRs) and damage associated molecular patterns (DAMPS) that activate caspase 1 which then signals for the secretion of pro-inflammatory cytokines IL-1β and IL-18 resulting in pyroptosis[3][4][5] Constant activation of the NLRP3 inflammasome is believed to play a direct or indirect role in acute arthritis, atherosclerosis and various neurodegenerative diseases such as multiple sclerosis (MS), Alzheimer's disease (AD), and Parkinson's disease (PD)[6],[2],.[7] This drug was developed by Olactec Therapeutics with the purpose of decreasing IL-1β peripheral inflammation by binding to the NLRP3 protein and inhibiting the formation of the NLRP3 inflammasome. Interestingly, dapansutrile has also been found to reduce levels of pro inflammatory cytokines IL-18 without interfering with TNF-α levels.[1] Stressed cells in the system can ignite the NLRP3 inflammasome which in turn produces the secretion inflammatory cytokines such as IL-1β and IL-18. Dapansutrile has tested in clinical trials and has been proposed as a beneficial compound for the remedy of osteoarthritis, and gouty arthritis.[1] Nevertheless, other preclinical research has proposed dapansutrile to be potentially beneficial for heart failure and multiple sclerosis.[1]